Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.3.1.900
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenue      
Medical devices $ 4,252 $ 2,924 $ 1,612
Engineering services 4,409 2,403 1,690
Total revenue 8,661 5,327 3,302
Cost of revenue      
Medical devices 3,926 2,048 1,461
Engineering services 3,556 1,720 1,254
Total cost of revenue 7,482 3,768 2,715
Gross profit 1,179 1,559 587
Operating expenses      
Sales and marketing 9,258 7,085 4,291
Research and development 6,480 3,868 2,677
General and administrative 7,002 7,400 3,913
Total operating expenses 22,740 18,353 10,881
Loss from operations (21,561) (16,794) (10,294)
Other income (expense)      
Interest expense (13) (435) (1,726)
Warrant issuance expense (487) 0 0
Gain (loss) on warrant liability 2,505 (16,485) 186
Interest income 11 6 5
Other expense, net (45) (61) (58)
Total other income (expense), net 1,971 (16,975) (1,593)
Net loss (19,590) (33,769) (11,887)
Less: Preferred deemed dividend 4,655 0 0
Net loss applicable to common shareholders $ (24,245) $ (33,769) $ (11,887)
Basic net loss per share (in dollars per share) $ (0.24) $ (0.43) $ (0.57)
Diluted net loss per share (in dollars per share) $ (0.26) $ (0.43) $ (0.57)
Weighted-average shares outstanding, basic (in shares) 102,241 78,264 20,977
Weighted-average shares outstanding, diluted (in shares) 102,265 78,264 20,977